Bioactive Technologies for Bone Replacement

The global market for orthobiologics, comprised primarily of bone replacement materials, reached almost $2 billion in 2009 and is growing at an overall rate of 7%. Medtronic leads in bone replacement with a 45% market share, but overall growth in orthobiologics may come from emerging segments, particular synthetic and stem-cell based technologies.

by Sharon O'Reilly

Once considered the Holy Grail in bone replacement materials, Medtronic PLC's Spinal and Biologics Division's INFUSE Bone Graft, the first bone growth factor approved for use in the US, raised the bar in terms of clinical efficacy and has dominated the market for bone replacement materials since its approval in 2002. This recombinant bone morphogenetic protein (rhBMP)-2 has the ability to induce bone growth across a repair site resulting in predictable healing and was PMA approved for use in conjunction with Medtronic's LT-CAGE for treating degenerative disc disease of the lumbar spine

More from Archive

More from Medtech Insight